1. Home
  2. CCLD vs CBIO Comparison

CCLD vs CBIO Comparison

Compare CCLD & CBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CCLD
  • CBIO
  • Stock Information
  • Founded
  • CCLD 1999
  • CBIO 2003
  • Country
  • CCLD United States
  • CBIO United States
  • Employees
  • CCLD N/A
  • CBIO N/A
  • Industry
  • CCLD Computer Software: Prepackaged Software
  • CBIO
  • Sector
  • CCLD Technology
  • CBIO
  • Exchange
  • CCLD Nasdaq
  • CBIO Nasdaq
  • Market Cap
  • CCLD 157.0M
  • CBIO 173.5M
  • IPO Year
  • CCLD 2014
  • CBIO N/A
  • Fundamental
  • Price
  • CCLD $3.50
  • CBIO $11.96
  • Analyst Decision
  • CCLD Buy
  • CBIO Strong Buy
  • Analyst Count
  • CCLD 2
  • CBIO 5
  • Target Price
  • CCLD $3.00
  • CBIO $25.60
  • AVG Volume (30 Days)
  • CCLD 478.8K
  • CBIO 136.6K
  • Earning Date
  • CCLD 11-11-2025
  • CBIO 11-23-2025
  • Dividend Yield
  • CCLD N/A
  • CBIO N/A
  • EPS Growth
  • CCLD N/A
  • CBIO N/A
  • EPS
  • CCLD 0.00
  • CBIO N/A
  • Revenue
  • CCLD $111,794,000.00
  • CBIO N/A
  • Revenue This Year
  • CCLD $6.94
  • CBIO N/A
  • Revenue Next Year
  • CCLD $18.66
  • CBIO N/A
  • P/E Ratio
  • CCLD $5,166.91
  • CBIO N/A
  • Revenue Growth
  • CCLD 0.04
  • CBIO N/A
  • 52 Week Low
  • CCLD $1.14
  • CBIO $10.83
  • 52 Week High
  • CCLD $4.84
  • CBIO $21.40
  • Technical
  • Relative Strength Index (RSI)
  • CCLD 58.81
  • CBIO 33.72
  • Support Level
  • CCLD $3.13
  • CBIO $10.96
  • Resistance Level
  • CCLD $3.85
  • CBIO $12.80
  • Average True Range (ATR)
  • CCLD 0.19
  • CBIO 0.58
  • MACD
  • CCLD -0.00
  • CBIO -0.10
  • Stochastic Oscillator
  • CCLD 69.45
  • CBIO 17.00

About CCLD CareCloud Inc.

CareCloud Inc delivers flexible, tech-enabled solutions for healthcare providers of all sizes and multi-specialties across the U.S. It is a healthcare technology company offering cloud-based solutions that simplify clinical, administrative, and financial workflows for medical practices of all sizes. Its comprehensive suite includes Electronic Health Records (EHRs), Practice Management, Revenue Cycle Management (RCM), Medical Billing, Telehealth, and Patient Experience solutions. The group helps practices increase efficiency, improve patient care, and drive sustainable growth-all while ensuring HIPAA compliance and seamless integration. The operating segments of the group are Healthcare IT, which is the key revenue-generating segment, and Medical Practice Management.

About CBIO Crescent Biopharma Inc. Common Stock

Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.

Share on Social Networks: